Quince Therapeutics, Inc. (QNCX) Operating cash flow 2018–2025
Quince Therapeutics, Inc. (QNCX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$41.4MFY2025 · since FY2018: -$11.7M → -$41.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$41.4M | -29.8% |
| FY2024 | -$31.9M | -74.4% |
| FY2023 | -$18.3M | +58.5% |
| FY2022 | -$44.0M | +30.0% |
| FY2021 | -$62.9M | -23.8% |
| FY2020 | -$50.8M | -52.7% |
| FY2019 | -$33.3M | -184.5% |
| FY2018 | -$11.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More QNCX financial trends
QNCX RevenueQNCX Net incomeQNCX Net marginQNCX Gross profitQNCX Gross marginQNCX Operating incomeQNCX Operating marginQNCX Free cash flowQNCX Capital expendituresQNCX Return on equityQNCX Stock buybacksQNCX Dividends paidQNCX Total assetsQNCX Total liabilitiesQNCX Shareholders’ equityQNCX overview →